Opdivo Qvantig

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Colorectal Cancer, Metastatic Colorectal Cancer, Advanced Colorectal Cancer, Advanced Metastatic Colorectal Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (4)
US
  • Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC).
    FDA label
  • Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by OPDIVO QVANTIG as monotherapy in the adjuvant setting after surgical resection.
    FDA label
  • Adults with unresectable or metastatic hepatocellular carcinoma (HCC) previously treated with sorafenib, following combination treatment with intravenous nivolumab and ipilimumabFDA label
Product first approved 2024
EU
  • Subcutaneous Opdivo (nivolumab co-formulated with rHuPH20), EU brand Opdivo SC; BMS release dated 28 May 2025; adult solid tumours incl. NSCLC
Product first approved 2025news.bms.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Renal Cell Carcinoma

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Advanced Colorectal Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Opdivo Qvantig: this drugApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Decoy20DiscontinuedBacterial immunotherapyMultiple Toll-like receptorsnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.